Differential responses of newborn pulmonary arteries and veins to atrial and C-type natriuretic peptides.
Atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) are important dilators of the pulmonary circulation during the perinatal period. We compared the responses of pulmonary arteries (PA) and veins (PV) of newborn lambs to these peptides. ANP caused a greater relaxation of PA than of PV, and CNP caused a greater relaxation of PV than of PA. RIA showed that ANP induced a greater increase in cGMP content of PA than CNP. In PV, ANP and CNP caused a similar moderate increase in cGMP content. Receptor binding study showed more specific binding sites for ANP than for CNP in PA and more for CNP than for ANP in PV. Relative quantitative RT-PCR for natriuretic peptide receptor A (NPR-A) and B (NPR-B) mRNAs show that, in PA, NPR-A mRNA is more prevalent than NPR-B mRNA, whereas, in PV, NPR-B mRNA is more prevalent than NPR-A mRNA. In conclusion, in the pulmonary circulation, arteries are the major site of action for ANP, and veins are the major site for CNP. Furthermore, the differences in receptor abundance and the involvement of a cGMP-independent mechanism may contribute to the heterogeneous effects of the natriuretic peptides in PA and PV of newborn lambs.
Tolsa
Jean-Francois
JF
Neonatal Research Laboratory, Division of Neonatology, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. Jean-Francois.Tolsa@chuv.hospvd.ch
Gao
Yuansheng
Y
Sander
Fred C
FC
Souici
Anne-Christine
AC
Moessinger
Adrien
A
Raj
J Usha
JU
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D006152:Cyclic GMP / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D006162:Guanylate Cyclase / Q000235:genetics*; D066298:In Vitro Techniques; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D020098:Natriuretic Peptide, C-Type / Q000494:pharmacology*; D009569:Nitric Oxide / Q000494:pharmacology; D010069:Oxadiazoles / Q000494:pharmacology; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology*; D011667:Pulmonary Veins / Q000187:drug effects / Q000502:physiology*; D011810:Quinoxalines / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012756:Sheep; D014158:Transcription, Genetic / Q000187:drug effects; D000099242:Atrial Natriuretic Factor Receptor B
D015056:1-Methyl-3-isobutylxanthine; D009320:Atrial Natriuretic Factor; D006152:Cyclic GMP; D006162:Guanylate Cyclase; D020098:Natriuretic Peptide, C-Type; D009569:Nitric Oxide; D010069:Oxadiazoles; D011810:Quinoxalines; D012333:RNA, Messenger; D017461:Receptors, Atrial Natriuretic Factor; D000099242:Atrial Natriuretic Factor Receptor B; C095284:1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; C091715:atrial natriuretic factor receptor A